NervGen’s investigational peptide therapeutic NVG-291 significantly improved functional performance and quality of life in patients with chronic spinal cord injury, positioning the drug for late-stage development.

The Canadian company will meet with the FDA early next year for end-of-Phase II deliberations and to align on NVG-291’s path forward, the biotech announced in a news release on Monday.

“Based on the clinical results observed in the CONNECT SCI Study, NVG-291 represents the first therapy demonstrating the ability to enable the nervous system to repair itself,” CEO Adam Rogers told BioSpace in an email on Monday.